Yapur V.M.,Area Gastroenterologia y Enzimologia Clinica |
Bustos M.F.,Area Gastroenterologia y Enzimologia Clinica |
Di Carlo M.B.,Area Gastroenterologia y Enzimologia Clinica |
Mingorance F.N.L.,Area Gastroenterologia y Enzimologia Clinica |
And 2 more authors.
Acta Bioquimica Clinica Latinoamericana | Year: 2013
Ceruloplasmin (CP) was reported to be an independent risk factor for cardiovascular disease. It has been identified as an acute phase protein and it carries about 95% of plasma copper. Myeloperoxidase (MPO), a leukocyte enzyme, has been listed as a potentially useful risk marker in acute coronary syndrome (ACS). More recently, it has been suggested that CP could be a physiological inhibitor of MPO. The aim of this study was to evaluate CP activity, MPO concentration, high sensitive C-reactive protein (CRP-hs) and Interleukine-6 (IL-6) in 22 patients with coronary arterial disease (CAD) and 22 control subjects and to analyze the association with other inflammatory parameters. CP activity was determined evaluating ferroxidase activity and MPO concentration, CRP-hs and IL-6 were measured by standardized methods. CP activity and MPO concentration were significantly higher in CAD patients than in healthy subjects (891±179 versus 630±115 IU/L, p<0.0001); (417±295 versus 179±145 ng/mL, p=0.0018), respectively. Significant association was found between MPO levels and CP activity (r=0.47, p=0.0272). Elevated MPO levels suggest that systemic release of MPO is a characteristic feature of asymptomatic coronary artery disease (CAD) and high CP activity could reflect subclinical atherosclerosis burden in patients who eventually develop symptomatic CAD.